Literature DB >> 3396612

In situ liver perfusion techniques: the significance of the anaesthetic procedure used.

T A Maguire1, J G Swanton, D J Temple.   

Abstract

Pentobarbitone may not be an appropriate anaesthetic to use on the donor rat of an isolated liver perfusion model intended to study drug-drug interactions, since the anaesthetic was found to remain in the liver in concentrations which may be high enough to modify the disposition of a test drug. A retrospective study to assess the anaesthetic pentobarbitone decay in six perfused rat livers, showed a linear correlation between perfusion medium concentrations of phenytoin and pentobarbitone at the early sample times, suggesting that the anaesthetic was inhibiting the hepatic clearance of phenytoin. Direct evidence for this inhibition was obtained following the addition of pentobarbitone (5 mg) to a standard perfusion experiment with phenytoin at t = 30 min. At the end of these experiments (t = 120 min), the perfusate phenytoin levels had decreased to only 18.6 +/- 3.7% of the initial concentration, compared to 5.6 +/- 2.5% in the control group. Pithing, under light ether anaesthesia, was investigated as an alternative preparatory procedure for the donor rat with potentially less effect on the liver. Phenytoin was found to be cleared from the perfusion medium more rapidly with livers thus prepared, especially in the early stages. Also the precision of the technique was improved; the standard errors for six replicate experiments being considerably less in the pithed group compared to the pentobarbitone anaesthetised group. This is clearly a more appropriate preparatory procedure for rat liver perfusion techniques designed to investigate drug metabolism. There may also be some advantages when the technique is to be used for other investigations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396612     DOI: 10.1007/BF03189926

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Simultaneous high-pressure liquid-chromatographic determination of some anticonvulsants in serum.

Authors:  R F Adams; F L Vandemark
Journal:  Clin Chem       Date:  1976-01       Impact factor: 8.327

2.  Metabolism of diphenylhydantoin by rat liver microsomes. I. characteristics of the reaction.

Authors:  H Kutt; K Verebely
Journal:  Biochem Pharmacol       Date:  1970-03       Impact factor: 5.858

3.  Enzyme induction in perfused rat liver by glucagon and other agents.

Authors:  W E Knox; C Sharma
Journal:  Enzymol Biol Clin (Basel)       Date:  1968

4.  The alcoholic metabolites of pentobarbital and amobarbital in man.

Authors:  E W Maynert
Journal:  J Pharmacol Exp Ther       Date:  1965-10       Impact factor: 4.030

5.  [The effect of diuretics on the choleresis of the biliary fistula rat and perfused liver of rat].

Authors:  P H Clodi; H Schnack
Journal:  Wien Klin Wochenschr       Date:  1966-11-11       Impact factor: 1.704

6.  Diethyl ether influence on the metabolism of antipyrine, paracetamol and sulphanilamide in isolated rat hepatocytes.

Authors:  H Aune; H Olsen; J Mørland
Journal:  Br J Anaesth       Date:  1981-06       Impact factor: 9.166

7.  Effect of diethylether on the formation of paracetamol sulphate and glucuronide in isolated rat hepatocytes.

Authors:  H Aune; P A Hals; B I Hansen; J Aarbakke
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

8.  Influence of amino acid supply on ribosomes and protein synthesis of perfused rat liver.

Authors:  L S Jefferson; A Korner
Journal:  Biochem J       Date:  1969-03       Impact factor: 3.857

9.  Effects of anesthetics on the hepatic metabolism and biliary secretion of lopanoic acid enantiomers in rat.

Authors:  W J Cooke; L M Cooke
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

10.  Gluconeogenesis in the perfused rat liver.

Authors:  R Hems; B D Ross; M N Berry; H A Krebs
Journal:  Biochem J       Date:  1966-11       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.